CSL Limited (ASX:CSL) has blamed an unfavourable exchange rate for the drop in profits, nonetheless reporting what the Managing Director calls an impressive result in a turbulent period.
For the full year to June 30, the biopharmaceutical company posted a net profit of $941 million. That’s 11 per cent lower than the year before. CSL expects similar trading conditions in fiscal 2012 to this year.
The company also announced the Chairman Elizabeth Alexander and Director David Simpson will retire from the board in October.
CSL will pay a final dividend of 45 cents, taking the total ordinary dividend to 80 cents.
